Company has also released its second quarter and first half financial results for the period ended June 30, 2021 NAPLES, Fla., Aug. 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
Read More
Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing…
Read More
NAPLES, Fla., June 3, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries (“MagicMed”),…
Read More
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with…
Read More
NAPLES, Fla., May 18, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patients,…
Read More
Cedars-Sinai Veteran Physician Joins Four Additional Clinical, Oncology and Cannabinoid Experts to Guide the Company’s Research and Scientific Programs NAPLES, Fla., May 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
Read More
NAPLES, FL / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today…
Read More
NAPLES, Fla., April 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that…
Read More
Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
Read More
– Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board – NEW YORK, March 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first…
Read More
